As of April 2024 Neurocrine Biosciences has a market cap of $13.97 Billion. This makes Neurocrine Biosciences the world's 1248th most valuable company by market cap according to our data. The market capitalization, commonly called market cap, is the total market value of a publicly traded company's outstanding shares and is commonly used to measure how much a company is worth.
Year | Market cap | Change |
---|---|---|
2024 | $13.97 B | 7.97% |
2023 | $12.94 B | 12.74% |
2022 | $11.48 B | 42.11% |
2021 | $8.07 B | -9.78% |
2020 | $8.95 B | -9.71% |
2019 | $9.91 B | 52.97% |
2018 | $6.48 B | -5.57% |
2017 | $6.86 B | 104.23% |
2016 | $3.36 B | -31.11% |
2015 | $4.87 B | 185.67% |
2014 | $1.70 B | 171.56% |
2013 | $0.62 B | 26.57% |
2012 | $0.49 B | 5.82% |
2011 | $0.46 B | 12.02% |
2010 | $0.41 B | 250.42% |
2009 | $0.11 B | -3.12% |
2008 | $0.12 B | -28.92% |
2007 | $0.17 B | -56.01% |
2006 | $0.39 B | -83.04% |
2005 | $2.32 B | 29.33% |
2004 | $1.80 B | -6.48% |
2003 | $1.92 B | 37.56% |
2002 | $1.40 B | -10.09% |
2001 | $1.55 B |
On Apr 24th, 2024 the market cap of Neurocrine Biosciences was reported to be:
Name | Market cap | Market cap differencediff. | Country |
---|---|---|---|
Pfizer PFE | $148.75 B | 964.24% | ๐บ๐ธ USA |
AbbVie ABBV | $297.11 B | 2,025.65% | ๐บ๐ธ USA |
Eli Lilly LLY | $696.15 B | 4,880.47% | ๐บ๐ธ USA |
Repligen
RGEN | $9.37 B | -32.94% | ๐บ๐ธ USA |
Athersys ATHX | $0.83 M | -99.99% | ๐บ๐ธ USA |
ANI Pharmaceuticals ANIP | $1.37 B | -90.18% | ๐บ๐ธ USA |
Palatin Technologies PTN | $27.91 M | -99.80% | ๐บ๐ธ USA |
Royalty Pharma RPRX | $16.71 B | 19.59% | ๐ฌ๐ง UK |